[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focal-seizure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focal-seizure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100636299","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-focus-1-100636299",false,"NCT07563881","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 1","Inclusion Criteria:\n\n1. Age 18 - 75\n2. BMI 18-45 kg\u002Fm2\n3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1\n4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis\n5. Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs\n6. Ability to keep accurate daily focal seizure records using an e-diary\n\nExclusion Criteria:\n\n1. Known hypersensitivity or prior exposure to RAP-219.\n2. Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur\n3. Anticipated need for surgery during the study period\n4. Medical history of any of the following:\n\n   1. generalized epilepsy\n   2. focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type\n   3. psychogenic nonepileptic seizure (PNES)\n   4. status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).\n   5. epilepsy surgery within 12 months prior to Visit 1 (Day -56).\n5. Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product","ALL","18 Years","75 Years",{"count":21,"type":22},333,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.",[28,29,30],"Focal Seizure","Epilepsy","Focal Epilepsy",[32,33],"Focal Preserved Consciousness","Focal Impaired Consciousness","RECRUITING","2026-08-12",{"date":37,"type":38},"2026-08-13","ACTUAL",{"date":40,"type":38},"2026-06-05",{"date":42,"type":22},"2029-09",{"name":44,"class":45},"Rapport Therapeutics Inc.","INDUSTRY",10,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":14,"acronym":52,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":26,"conditions":56,"keywords":57,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":65},"100643647","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-100643647","NCT07594119","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 2",{"count":54,"type":22},312,[25],[28,29,30],[32,33],"2026-08-04",{"date":60,"type":38},"2026-08-05",{"date":62,"type":22},"2026-08",{"date":42,"type":22},{"name":44,"class":45},6,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100609809","phase-2-a-long-term-study-of-the-safety-and-effectiveness-of-rap-219-in-adults-with-focal-onset-seizures-100609809","NCT07219407","A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","Inclusion Criteria:\n\n* Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.\n* Diagnosis of refractory focal epilepsy\n* Stable RNS(c) system settings\n* A demonstrated history of compliance with RNS(c) system data interrogation and upload\n* Good overall health other than focal epilepsy, per Investigator.\n* BMI ≥ 18 kg\u002Fm\\^2 and ≤ 45 kg\u002Fm\\^2\n* Willing and able to adhere to all aspects of the protocol.\n\nExclusion Criteria:\n\n* Known of hypersensitivity to RAP-219\n* Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator\n* Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods","70 Years",{"count":75,"type":22},30,[77],"PHASE2","This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.",[30,29,80,81,28,82],"Refractory Focal Epilepsy","Seizure","Focal Onset Seizure",[84,29,85,86],"Focal Seizures","RNS","Long episode","2026-01-22",{"date":89,"type":38},"2026-01-23",{"date":91,"type":38},"2025-12-15",{"date":93,"type":22},"2028-02-03",{"name":44,"class":45},7]